3 Einträge gefunden

1. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study

   1. Lonial, Sagar
   2. Lee, Hans C
   3. Badros, Ashraf
   4. Trudel, Suzanne
   5. Nooka, Ajay K
   6. Chari, Ajai
   7. Abdallah, Al-Ola

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
2. Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design

   1. Nooka, Ajay K
   2. Weisel, Katja
   3. van de Donk, Niels Wcj
   4. Routledge, David
   5. Otero, Paula Rodriguez
   6. Song, Kevin
   7. Quach, Hang

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
3. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

   1. Lonial, Sagar
   2. Lee, Hans C
   3. Badros, Ashraf
   4. Trudel, Suzanne
   5. Nooka, Ajay K
   6. Chari, Ajai
   7. Abdallah, Al-Ola

   2020 - Forschungsinformationssystem des UKE